Commitments and Contingencies (Additional Information) (Details) - USD ($)					1 Months Ended		3 Months Ended		12 Months Ended
	Apr. 02, 2026	Mar. 11, 2026	Aug. 20, 2025	Jun. 11, 2024	Nov. 30, 2025	Feb. 28, 2013	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025	Jan. 29, 2026	Aug. 31, 2025	Aug. 17, 2025
Commitments and Contingencies [Line Items]
Common Stock Share Price							$ 630
Royalty expenses							$ 0	$ 100,000
Prepayment costs		$ 100,000,000
Finance lease liabilities							$ 0
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]							Derivative Liability, Noncurrent
Lease Expense							$ 1,200,000	300,000
Implementation fee related to sales							72,000
Implementation fee of First Year							1,200,000
Implementation fee of Second And Third Year							1,300,000
Long Term Commitment Amount				$ 100,000,000
Non-refundable deposit					$ 2,500,000
Impairment Loss							0		$ 2,500,000
Former Employee [Member]
Commitments and Contingencies [Line Items]
Agreement settlement payment							3,500,000
Former Employee One[Member]
Commitments and Contingencies [Line Items]
Agreement settlement payment							$ 2,500,000
Mr. Mack [Member] \| Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Payment for attorneys fees	$ 5,300,000
Common Stock [Member]
Commitments and Contingencies [Line Items]
Common Stock Share Price			$ 16
Investor agreed to purchase Share			1,250,000
Aggregate purchase price			$ 20,000,000
Probudur [Member]
Commitments and Contingencies [Line Items]
Percentage on net sale							6.00%
Envelta [Member]
Commitments and Contingencies [Line Items]
Percentage on net sale							6.00%
Epoladerm [Member]
Commitments and Contingencies [Line Items]
Percentage on net sale							6.00%
Product Development Agreement [Member] \| Developers [Member]
Commitments and Contingencies [Line Items]
Royalty expenses							$ 900,000	700,000
Accrued royalty payables							$ 1,800,000		2,100,000
Agreement maturity date						Oct. 02, 2028
Agreement maturity renewal description							The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon six-months’ written notice.
Product Development Agreement [Member] \| Developers [Member] \| Minimum
Commitments and Contingencies [Line Items]
Royalty payment percentage related to future years							25.00%
Product Development Agreement [Member] \| Developers [Member] \| Maximum
Commitments and Contingencies [Line Items]
Royalty payment percentage related to future years							35.00%
Product Development Agreement [Member] \| Scilex Pharma [Member]
Commitments and Contingencies [Line Items]
Royalty expenses							$ 1,200,000	$ 900,000
Non-cancelable Lease Agreements [Member] \| Minimum \| Research and Development Facilities [Member]
Commitments and Contingencies [Line Items]
Operating lease, remaining lease term							1 year 6 months
Operating lease, lease term							1 year
Non-cancelable Lease Agreements [Member] \| Maximum \| Research and Development Facilities [Member]
Commitments and Contingencies [Line Items]
Operating lease, lease term							13 years
Investment Agreement
Commitments and Contingencies [Line Items]
Contingent consideration, liability									1,000,000		$ 2,500,000
Investment Agreement \| PA OPS Investor LLC [Member]
Commitments and Contingencies [Line Items]
Contingent consideration, liability							$ 2,500,000		2,500,000			$ 2,500,000
Long Term Commitment Amount							$ 2,500,000		$ 2,500,000
Loan interest rate							4.03%		4.03%
Common Stock Purchase Agreement [Member]
Commitments and Contingencies [Line Items]
Common Stock Share Price										$ 0.14247
Common Stock Share Purchases										193,021,436
Payments for Purchase of Common Stock										$ 27,500,000

Scilex Holding Co 10-Q